Xilio Therapeutics
MA - WalthamBiotechnology
Focus: Xilio Therapeutics is a clinical-stage oncology biotech focused on cancer immunotherapies, headquartered in Waltham, MA. The company is NASDAQ-listed (ticker: XLO) and actively building its pipeline in advanced solid tumors and NSCLC.
Profile data last refreshed 16h ago · AI intelligence enriched 4d ago
Open Jobs
1+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at Xilio Therapeutics?
AI assessmentXilio is a high-risk, high-upside opportunity for immunology specialists seeking early-stage clinical development exposure in oncology, but career stability depends entirely on pipeline execution and continued capital access.
Why Work Here
- Early-stage immunotherapy pipeline with 4 programs in Phase 1/2, offering hands-on involvement in clinical development before major inflection points
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
XTX202
Advanced Solid TumorClinical Trials (1)
NCT05052268XTX202 in Patients With Advanced Solid Tumors
Phase 1/2Help build intelligence for Xilio Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.